Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

KAYA A. H., TEKGÜNDÜZ A. İ. E., İLKKILIÇ K., DAL M. S., MERDİN A., KARAKUŞ A., ...Daha Fazla

JOURNAL OF CHEMOTHERAPY, cilt.30, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/1120009x.2017.1396017
  • Dergi Adı: JOURNAL OF CHEMOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Acute myeloid leukaemia, AML, Relapse, Refractory, Clofarabine, STEM-CELL TRANSPLANTATION, HIGH-DOSE CYTARABINE, CLOFARABINE, REMISSION, RECOMMENDATIONS, DIAGNOSIS, SURVIVAL, ADULTS
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

We hereby report our multicentre, retrospective experience with CLARA in patients with fludarabine/cytarabine/GCSF (FLAG) refractory AML. The study included all consecutive R/R AML patients, who received CLARA salvage during October 2010-October 2015 period. All patients were unresponsive to FLAG salvage chemotherapy regimen and did not undergo previous allo-HCT. A total of 40 patients were included. Following CLARA 5 (12.5%) patients experienced induction mortality and 10 (25%) patients achieved CR. 25 (62.5%) patients were unresponsive to CLARA. 7 (17.5%) out of 10 patients in CR received allo-HCT. Median overall survival of patients who achieved CR after CLARA was 24.5 months (8.5-54.5) and 3 months (2.5-5), in patients who underwent and didn't allo-HCT, respectively. Our results indicate that CLARA may be good alternative even in FLAG refractory AML patients and can be used as a bridge to allo-HCT, who have a suitable donor and able to tolerate the procedure.